Thema: US31189P1021
FATE, US31189P1021
thai-1549085_1920.jpg - Foto: THN
Fate Therapeutics stock: New hires receive 300,000 options
Fate Therapeutics stock follows a new employee award package announced on November 3. The grants carry four-year vesting schedules.
ad-hoc-news.de, vor 58 Minuten
FATE, US31189P1021
Fate Therapeutics reports USD 2.08 million revenue for stock ...
Second-quarter revenue reached USD 2.08 million against USD 2.05 million consensus. Fate Therapeutics stock costs EUR 1.85 on October 20, 2026.
ad-hoc-news.de, 20.10.26 21:40 Uhr
FATE, US31189P1021
Fate Therapeutics stock fell 7.01 percent on October 16 ...
Analysts kept the USD 5.90 average target on October 16, 2026. Fate Therapeutics stock stood at USD 1.79 on October 16, 2026, down 7.01 percent on Nasdaq.
ad-hoc-news.de, 17.10.26 21:05 Uhr
FATE, US31189P1021
Fate Therapeutics stock stands 97.96 percent higher year ...
Second-quarter revenue was USD 2.08 million. Fate Therapeutics stock costs EUR 1.71 on October 15, 2026, down 1.10 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 18:44 Uhr
FATE, US31189P1021
Fate Therapeutics grants employee awards: what it means ...
The awards covered 62,900 options and 72,700 RSUs on October 1, 2026. Fate Therapeutics stock had a EUR 2.04 prior close on October 5, 2026.
ad-hoc-news.de, 07.10.26 04:05 Uhr
FATE, US31189P1021
Fate Therapeutics stock adds two Q4 conference dates
Fate Therapeutics stock closed at USD 2.43 on October 5, 2026, while analysts set an average target of USD 5.90. Q2 revenue reached USD 2.08 million.
ad-hoc-news.de, 07.10.26 00:20 Uhr
